Literature DB >> 1500216

Human carcinoembryonic antigen cDNA expressed in rat carcinoma cells can function as target antigen for tumor localization of antibodies in nude rats and as rejection antigen in syngeneic rats.

A Pèlegrin1, A Terskikh, D Hayoz, Y Chalandon, N O Olsson, S Folli, F Buchegger, B Kromer, K Schwarz, M Martin.   

Abstract

We have tried to develop a new model consisting of rats transplanted with syngeneic colon carcinoma PROb cells transfected with cDNA coding for the carcinoembryonic antigen (CEA), the human tumor marker most commonly used as target for MAbs. The antigenic density of the 4 CEA-expressing clones selected for a precise characterization ranged from 5 x 10(4) to 1 x 10(6) CEA molecules per cell. In all clones the CEA was shown to be attached to the membrane by a phosphatidylinositol (PI) anchor. Using a panel of radiolabeled MAbs directed against the 5 major epitopes described on the CEA molecule, we showed that all these CEA epitopes were expressed by the 4 transfectants. Southern-blot analysis showed that the entire CEA cDNA was present in the transfectants. Western-blot analysis, however, showed that the size of the CEA expressed by the 4 transfectants was slightly smaller than that of CEA produced by 2 reference human colon-carcinoma cell lines. Two clones, expressing 1 x 10(5) and 1 x 10(6) CEA molecules per cell, respectively, were grafted s.c. in nude mice and rats. Injection of radiolabeled anti-CEA F(ab')2 fragments into these animals showed specific tumor localization with the highest percentages of injected doses for the transfectants expressing the highest CEA level. When grafted into immunocompetent syngeneic BDIX rats, the CEA-expressing clones induced a strong antibody response against CEA and tumor rejections in a majority of the animals. Although the analysis of the immune response against the CEA-cDNA-transfected carcinoma cells is under investigation, the present results demonstrate that human CEA could function as a rejection antigen when transfected into rat carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1500216     DOI: 10.1002/ijc.2910520120

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein.

Authors:  Claire Germain; Emmanuelle Campigna; Imed Salhi; Sébastien Morisseau; Isabelle Navarro-Teulon; Jean-Pierre Mach; André Pèlegrin; Bruno Robert
Journal:  Protein Eng Des Sel       Date:  2008-09-11       Impact factor: 1.650

2.  Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis.

Authors:  Lore Santoro; Samir Boutaleb; Véronique Garambois; Caroline Bascoul-Mollevi; Vincent Boudousq; Pierre-Olivier Kotzki; Monique Pèlegrin; Isabelle Navarro-Teulon; André Pèlegrin; Jean-Pierre Pouget
Journal:  J Nucl Med       Date:  2009-11-12       Impact factor: 10.057

3.  Internalisation enhances photo-induced cytotoxicity of monoclonal antibody-phthalocyanine conjugates.

Authors:  M Carcenac; M Dorvillius; V Garambois; F Glaussel; C Larroque; R Langlois; N E Hynes; J E van Lier; A Pèlegrin
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

4.  Involvement of circulating CEA in liver metastases from colorectal cancers re-examined in a new experimental model.

Authors:  A Leconte; V Garambois; M Ychou; B Robert; D Pourquier; A Terskikh; J P Mach; A Pèlegrin
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

5.  Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab')2 fragment in nude mice bearing different human colon cancer xenografts.

Authors:  C A Vogel; A Bischof-Delaloye; J P Mach; A Pèlegrin; N Hardman; B Delaloye; F Buchegger
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.